Q2 FY2026 EarningsQ2 FY2026 results missed consensus on the top-line, with revenue of $0.41M vs. $1.11M expected, though Symvess sales grew 300% YoY. GAAP EPS of -$0.16 missed the -$0.10 estimate, primarily due to non-cash remeasurements and a $0.7M inventory reserve. Despite the financial miss, the company reported breakthrough Phase 3 results for its dialysis access trial and plans an sBLA filing in 2H 2026, while securing $57.5M in new capital to extend its runway.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Humacyte(HUMA) the Revenue is 406 K (+34.88%), Miss estimate;the EBIT is -27 M (+9.19%), Miss estimate;the EPS is -0.16 (+33.33%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueMiss expectations
0.00B34.88%
0.00B269.70%
-0.00B234.82%
EBITMiss expectations
-0.03B9.19%
-0.02B25.74%
-0.00B16.55%
EPSMiss expectations
-0.1633.33%
-0.158.33%
-0.060025.00%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf